EUCTR2011-004017-17-GB进行中（未招募）1 期
Prospective, Single-centre, Open-Label, Randomised, Pilot Study Assessing the changes in expression of JAK-STAT and Speed & Depth of Remission Induced by Tocilizumab & Methotrexate Combination and Tocilizumab Monotherapy in Patients with Early Rheumatoid Arthritis (TREMERA). - TREMERA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Diagnosis of rheumatoid arthritis (2010 ACR/EULAR RA classification criteria) 2.Symptom duration =12months 3. No previous disease modifying anti-rheumatic drug (DMARD) therapy 4. Active RA at baseline (defined as: DAS28 = 3.2) 5. Active hand and/or wrist joint evaluable by US and MRI (with no planned surgery during the study period) 6. Patients without any contraindication to MRI
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1.Patients unwilling or unable to receive MTX for the duration of the study. 2.Patients with inflammatory joint disease of different origin, mixed connective tissue disease, Reiter’s syndrome, psoriatic arthritis, systemic lupus erythematosis, or any arthritis with onset prior to 16 years of age. 3.Suspicion of diagnosis of tuberculosis: positive quantiferon +/- abnormal chest x-ray – as per clinician judgement. Prior history of TB with confirmed full chemotherapy +/- latent TB adequately treated may be included as per physician’s discretion. 4.Intramuscular, oral or intra-articular (of non-target joint) corticosteroid within 28 days of the screening visit; intra-articular steroid of the chosen target joint within 12 weeks of screening. 5. Patients with serious infections within 3 month of enrolment (screening) or persistent infections. 6. Patients at significant risk of infection (e.g. leg ulceration, indwelling urinary catheter, septic joint within 1 year (or ever if prosthetic joint still in situ). 7. Known positive serology for hepatitis B or C, or HIV
研究者
相似试验
尚未招募
不适用
Prospective, Randomized, Open-label, Single center, Case Control Study To Evaluate Impact Of Eglandin® (Alprostadil) On Incidence Of Antibody-mediated Rejection According To Length Of Use In ABO-incompatible Living Donor Liver Transplant PatientKCT0006115Asan Medical Center160
已完成
不适用
Single Center,Study on Evaluation of use of,â??AYURCOVâ?? as add on therapy for Treatment of SARS-CoV-2 Infection in COVID-19 Patients,at Tertiary Care Center.CTRI/2020/06/026262Bhaktivedanta Hospital and Research Institute120
已完成
不适用
Dente 91 Mom Toothpaste and Mouthwash study on dental health of pregnant females.CTRI/2022/07/044117Dr Faiza Tekrawala30
已完成
不适用
A Prospective, Multicenter, Open-Label, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-Abdominal Infections in Adults-A499 Bacterial infection, unspecifiedBacterial infection, unspecifiedA499PER-063-01MERCK SHARP & DOHME PERU S.R.L.,
已完成
不适用
Ertapenem versus Ceftriaxone and Metronidazole As Treatment For Complicated Intra-abdominal InfectionsComplicated intra-abdominal infectionsInfections and InfestationsOther and unspecified infectious diseasesISRCTN59616541Merck and Co., Inc. (USA)500